Beneficial Effects of Control-IQ Automated Insulin Delivery in Basal-Bolus and Basal-Only Insulin Users With Type 2 Diabetes.

Carol J LevyDan RaghinaruYogish C KudvaKeta PanditThomas BlevinsLuis CasaubonDonna DesjardinsCamilla M LevisterGrenye O'MalleyCorey ReidJohn W LumCraig KollmanRoy W Beck

Published in: Clinical diabetes : a publication of the American Diabetes Association (2023)

The t:slim X2 insulin pump with Control-IQ technology (Control-IQ) advanced hybrid closed-loop automated insulin delivery system was evaluated in this prospective single-arm trial. Thirty adults with type 2 diabetes using the Control-IQ system showed substantial glycemic improvement with no increase in hypoglycemia. Mean time in range (70-180 mg/dL) improved 15%, representing an increase of 3.6 hours/day, and mean glucose decreased by 22 mg/dL.

Keyphrases

type diabetes
glycemic control
deep learning
clinical trial
blood glucose
insulin resistance
study protocol
adipose tissue
phase iii
phase ii
weight loss